Skip to main content

Table 1 Clinical, treatment and dosimetric parameters

From: Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer

 

Median (range)

Count (%)

Continuous variables

  

  Age (years)

70 (54–86)

 

  Initial PSA (ng/mL)

11.95 (3.7–48.0)

 

  Positive biopsy rate (%)

33.0 (13.0–100)

 

  Prostate D90 (Gy)

124.8 (100.0–206.5)

 

  BED (Gy2)

213.5 (178.5–245.5)

 

Categorical variables

  

  PSA level in ng/mL

  

   <10

 

86 (41.7%)

   10-20

 

39 (19.0%)

   ≥ 20

 

81 (39.3%)

  Gleason score

  

   5-6

 

26 (12.6%)

   7

 

54 (26.2%)

   8-10

 

126 (61.2%)

  Clinical T stage

  

   T1-T2a

 

142 (69.0%)

   T2b-T2c

 

46 (22.4%)

   T3a

 

18 (8.6%)

  No. of high-risk features

  

   1

 

186 (90.3%)

   2

 

19 (9.2%)

   3

 

1 (0.5%)

  Neoadjuvant ADT

  

   Yes

 

101 (49.0%)

  1. Abbreviations: PSA = prostate specific antigen; D90 = the minimal dose received by 90% of the prostate; BED = biologically effective dose; ADT = androgen deprivation therapy.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us